Abstract
Restenosis, the re-narrowing of a blood vessel after removal of atherosclerotic plaque, is a major limitation of surgical treatments for atherosclerosis. Various attempts to prevent or treat restenosis by pharmacological or mechanical approaches have had limited success in clinical trials. Hence, there is wide interest in developing new strategies to prevent or treat restenosis. This review discusses ‘a new-generation therapy’ that uses functional nanoparticles to effectively deliver active drug molecules. The potential platforms for nanoparticle-based solutions to restenosis include organic (e.g. polymers, liposomes, and proteins) and inorganic nanoparticles (e.g. layered double hydroxides, titanium oxide nanotubes, and magnetic nanoparticles,). Many in vitro and in vivo studies based on these platforms demonstrate the feasibility and potential of using nanoparticle drug delivery systems for preventing or treating restenosis, but as yet few have reached clinical trials. It is suggested that using inorganic nanoparticles to target deliver multi-functional drugs will be a promising approach to preventing or treating restenosis.
Keywords: Restenosis, nanoparticle, drug delivery, layered double hydroxide.
Current Pharmaceutical Design
Title:Restenosis Treatments Using Nanoparticle-based Drug Delivery Systems
Volume: 19 Issue: 35
Author(s): Zi Gu, Barbara E. Rolfe, Anita C. Thomas and Zhi Ping Xu
Affiliation:
Keywords: Restenosis, nanoparticle, drug delivery, layered double hydroxide.
Abstract: Restenosis, the re-narrowing of a blood vessel after removal of atherosclerotic plaque, is a major limitation of surgical treatments for atherosclerosis. Various attempts to prevent or treat restenosis by pharmacological or mechanical approaches have had limited success in clinical trials. Hence, there is wide interest in developing new strategies to prevent or treat restenosis. This review discusses ‘a new-generation therapy’ that uses functional nanoparticles to effectively deliver active drug molecules. The potential platforms for nanoparticle-based solutions to restenosis include organic (e.g. polymers, liposomes, and proteins) and inorganic nanoparticles (e.g. layered double hydroxides, titanium oxide nanotubes, and magnetic nanoparticles,). Many in vitro and in vivo studies based on these platforms demonstrate the feasibility and potential of using nanoparticle drug delivery systems for preventing or treating restenosis, but as yet few have reached clinical trials. It is suggested that using inorganic nanoparticles to target deliver multi-functional drugs will be a promising approach to preventing or treating restenosis.
Export Options
About this article
Cite this article as:
Gu Zi, Rolfe E. Barbara, Thomas C. Anita and Xu Ping Zhi, Restenosis Treatments Using Nanoparticle-based Drug Delivery Systems, Current Pharmaceutical Design 2013; 19 (35) . https://dx.doi.org/10.2174/1381612811319350009
DOI https://dx.doi.org/10.2174/1381612811319350009 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiplatelet Treatment in Peripheral Arterial Disease: The Role of Novel Antiplatelet Agents
Current Pharmaceutical Design Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Interrelationship between Chronic Kidney Disease and Risk of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Milk Thistle: A Future Potential Anti-Osteoporotic and Fracture Healing Agent
Current Drug Targets Apoptosis-Inducing Activity of the S100A8/A9 Heterodimer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Antiplatelet Therapy in Acute Coronary Syndromes. Evidence Based Medicine
Current Pharmaceutical Design Contemporary Risk Assessment and Cardiovascular Outcomes in Peripheral Arterial Disease
Cardiovascular & Hematological Disorders-Drug Targets Modulators of Networks: Molecular Targets of Arterial Calcification Identified in Man and Mice
Current Pharmaceutical Design Brachial-Ankle Pulse Wave Velocity as a Novel Measure of Arterial Stiffness: Present Evidences and Perspectives
Current Hypertension Reviews Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease
Current Genomics Editorial [Hot topic: Current Status of Drug Eluting Stents (Executive Editor: Nicholas Kipshidze)]
Current Pharmaceutical Design Nutri-epigenomic Studies Related to Neural Tube Defects: Does Folate Affect Neural Tube Closure Via Changes in DNA Methylation?
Mini-Reviews in Medicinal Chemistry Human Chorionic Gonadotropin: A Model Molecule For Oligopeptide-Based Drug Discovery
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacotherapy for Intermittent Claudication: From Consensus-Based to Evidence-Based Treatment
Vascular Disease Prevention (Discontinued) Advances in L-Type Calcium Channel Structures, Functions and Molecular Modeling
Current Medicinal Chemistry Current Understanding of Dietary Polyphenols and their Role in Health and Disease
Current Nutrition & Food Science Vascular Abnormalities in Essential Hypertension
Current Pharmaceutical Design Expressions of eNOS3 and Ve-Cadherin in Microvascular Endothelium at 7-Day of Reperfused Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets High Resolution M-mode Evaluation of Jugular Vein Valves in Patients with Neurological and Neurosensory Disorders
Current Neurovascular Research